This study is testing a drug called obexelimab to see if it is safe and effective for people with Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease. Obexelimab works by targeting specific cells (B cells) that play a role in SLE. You might be able to join if you are between 18 and 70 years old, have been diagnosed with SLE for at least 24 weeks, and have active symptoms. The main goal is to see how well obexelimab works after 24 weeks of treatment. The study is currently unclear on its recruitment status and plans to enroll about 190 participants.

Study design

This study is an interventional trial with 190 planned participants. Participants will be randomly assigned to receive either obexelimab or a placebo.

What's involved

You would receive weekly injections for 24 weeks, with scheduled visits every 2-4 weeks. Your total participation, including screening and follow-up, would be about 40 weeks.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 12 weeks after the 24-week treatment period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.